AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36239434 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influences
Number of subjects: 81
Study 36239434 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 81
Study 32102685 — intervention group
Group type: EXPERIMENTAL
Intervention: VR‐avoidance training
Number of subjects: 100
Study 32102685 — intervention group
Group type: COMPARATOR
Intervention: VR‐placebo training
Number of subjects: 100
Study 35253581 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive physiotherapy (CP) - 12 sessions, supervised (n=22)
Number of subjects: 50
Study 35253581 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (SCI) - 1cc triamhexal (n=25)
Number of subjects: 50
Study 34182804 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of religion and spirituality (R/S) in health care communications
Number of subjects: 29
Study 32667287 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban treatment for 7 days
Number of subjects: 60
Study 32667287 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 60
Study 32667287 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban treatment
Number of subjects: 60
Study 34464575 — intervention group
Group type: EXPERIMENTAL
Intervention: ONSTEP
Number of subjects: 100
Study 34464575 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 100
Study 36404303 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 211
Study 35115825 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB) with Opioid Free Anesthesia (OFA)
Number of subjects: 40
Study 35115825 — intervention group
Group type: COMPARATOR
Intervention: Conventional balanced anesthesia with opioids
Number of subjects: 40
Study 33507513 — intervention group
Group type: EXPERIMENTAL
Intervention: Compost at 35 t/ha
Number of subjects: 8
Study 33507513 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochar only (5 t/ha)
Number of subjects: 8
Study 33507513 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochar mixed with compost (5 t/ha and 10 t/ha)
Number of subjects: 8
Study 33507513 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 33507513 — intervention group
Group type: EXPERIMENTAL
Intervention: Compost at 10 t/ha and 25 t/ha
Number of subjects: 8
Study 33507513 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 8
Study 32989795 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg twice daily coadministered with rifabutin
Number of subjects: 0
Study 32989795 — intervention group
Group type: COMPARATOR
Intervention: Doravirine 100 mg once daily
Number of subjects: 0
Study 33407788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung meridian group
Number of subjects: 68
Study 33407788 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart meridian group
Number of subjects: 68
Study 35370460 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomolecules-enriched Mediterranean Buffalo milk and its derived dairy foods (treated group)
Number of subjects: 20
Study 35370460 — intervention group
Group type: COMPARATOR
Intervention: Cow milk and its dairy products (control group)
Number of subjects: 20
Study 33627168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 500
Study 32086985 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of an encecalin standardized extract of Ageratina pichinchensis for 6 months
Number of subjects: 0
Study 32086985 — intervention group
Group type: COMPARATOR
Intervention: 8% ciclopirox (control group) for 6 months
Number of subjects: 0
Study 33461967 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34456283 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of bisphosphonate gel
Number of subjects: 27
Study 34456283 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of recombinant human bone morphogenic protein 2 gel
Number of subjects: 27
Study 34456283 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of a mixed formula of both gels
Number of subjects: 27
Study 34456283 — intervention group
Group type: COMPARATOR
Intervention: Implant insertion without application of any medication (Control)
Number of subjects: 27
Study 34225535 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min moderate-intensity exercise (E20 session)
Number of subjects: 18
Study 34225535 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min moderate-intensity exercise (E40 session)
Number of subjects: 18
Study 33058172 — intervention group
Group type: COMPARATOR
Intervention: Implementation interventions (compared to no intervention)
Number of subjects: 12428
Study 33058172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation interventions (compared to non-tailored interventions)
Number of subjects: 12428
Study 33058172 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation interventions (compared to another implementation intervention)
Number of subjects: 12428
Study 33277982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 80
Study 33277982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32057490 — intervention group
Group type: EXPERIMENTAL
Intervention: BPPV diagnosis and treatment system
Number of subjects: 230
Study 32057490 — intervention group
Group type: COMPARATOR
Intervention: Manual repositioning
Number of subjects: 230
Study 35512719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric haemagglutinin influenza split‐virion vaccines adjuvanted with AS01
Number of subjects: 0
Study 35512719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric haemagglutinin influenza split‐virion vaccines adjuvanted with AS03
Number of subjects: 0
Study 35512719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric haemagglutinin influenza split‐virion vaccines non‐adjuvanted
Number of subjects: 0
Study 32967605 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education program (3 sessions)
Number of subjects: 59
Study 32967605 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 59
Study 35703882 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (bisoprolol 10 mg or atenolol 100 mg)
Number of subjects: 56
Study 33854050 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT (nine sessions)
Number of subjects: 40
Study 35833327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 10
Study 35833327 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 10
Study 33434094 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent Video Games (VVGs)
Number of subjects: 87
Study 33434094 — intervention group
Group type: COMPARATOR
Intervention: Nonplayers (Control)
Number of subjects: 87
Study 35445090 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided revascularization of non-culprit stenoses
Number of subjects: 200
Study 35445090 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided revascularization of non-culprit stenoses
Number of subjects: 200
Study 33452060 — intervention group
Group type: EXPERIMENTAL
Intervention: ED safety questionnaire
Number of subjects: 1060
Study 33452060 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses from nurses and doctors
Number of subjects: 1060
Study 33888367 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated-humidified CO2 (95% humidified insufflation at 37 °C)
Number of subjects: 96
Study 33888367 — intervention group
Group type: COMPARATOR
Intervention: Standard CO2 (cold-dry)
Number of subjects: 96
Study 32054468 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with Salvadora persica (miswak) sticks
Number of subjects: 94
Study 32054468 — intervention group
Group type: COMPARATOR
Intervention: Brushing with fluoridated toothpaste (FTP)
Number of subjects: 94
Study 35691249 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HF) with simultaneous integrated boost (SIB) after breast-conserving surgery (BCS)
Number of subjects: 274
Study 34180428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 30
Study 34180428 — intervention group
Group type: COMPARATOR
Intervention: Sham Mirror Therapy (C)
Number of subjects: 30
Study 32448552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Intervention
Number of subjects: 46
Study 32448552 — intervention group
Group type: COMPARATOR
Intervention: Wellness Control
Number of subjects: 46
Study 35771961 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (SG) - offered PSA testing every 2 years
Number of subjects: 20000
Study 35771961 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no organized screening
Number of subjects: 20000
Study 34158965 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Health Communication Application (IHCA)
Number of subjects: 140
Study 34158965 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 34158965 — intervention group
Group type: EXPERIMENTAL
Intervention: IHCA
Number of subjects: 140
Study 34158965 — intervention group
Group type: EXPERIMENTAL
Intervention: IHCA and Usual care
Number of subjects: 140
Study 33040810 — intervention group
Group type: EXPERIMENTAL
Intervention: Floium ginkgo extract and tertram ethypyrazine sodium chloride injection
Number of subjects: 200
Study 33040810 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment measures
Number of subjects: 200
Study 36196779 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist recommendations during the intervention period
Number of subjects: 146
Study 36196779 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist recommendations
Number of subjects: 146
Study 36196779 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions made by clinical pharmacist
Number of subjects: 146
Study 32481404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bukuryoingohangekobokuto (BRIHK)
Number of subjects: 24
Study 32481404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32011301 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone at a maintenance dose for one year (n=60)
Number of subjects: 80
Study 32011301 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving digoxin and bisoprolol (n=20)
Number of subjects: 80
Study 34271110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (reference group)
Number of subjects: 70129
Study 34271110 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 70129
Study 32331015 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (viewed video of actor with mild-to-moderate TD movements)
Number of subjects: 800
Study 32331015 — intervention group
Group type: COMPARATOR
Intervention: Control group (viewed video of actor without TD movements)
Number of subjects: 800
Study 36124702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 1157
Study 36124702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (all doses)
Number of subjects: 1157
Study 33499888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise and psychological support after COVID-19 infection
Number of subjects: 0
Study 32464043 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Number of subjects: 0
Study 32464043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgical and systemic therapies
Number of subjects: 0
Study 32464043 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of primary tumor and metastatic deposits
Number of subjects: 0
Study 35250338 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES+ (neuromuscular electrical stimulation superimposed on functional exercises)
Number of subjects: 34
Study 35250338 — intervention group
Group type: COMPARATOR
Intervention: NAT (no additional training to traditional rehabilitation)
Number of subjects: 34
Study 36345825 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Domain Rehabilitation Intervention
Number of subjects: 349
Study 36345825 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 349
Study 33751702 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative messages
Number of subjects: 26560
Study 33751702 — intervention group
Group type: EXPERIMENTAL
Intervention: Social messages
Number of subjects: 26560
Study 33751702 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal messages
Number of subjects: 26560
Study 33751702 — intervention group
Group type: EXPERIMENTAL
Intervention: In-account messages
Number of subjects: 26560
Study 33751702 — intervention group
Group type: EXPERIMENTAL
Intervention: Limit-setting
Number of subjects: 26560
Study 33751702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messages)
Number of subjects: 26560
Study 33849618 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 33849618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 33849618 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30
Study 33849618 — intervention group
Group type: COMPARATOR
Intervention: Control (constant MAC)
Number of subjects: 30
Study 33148541 — intervention group
Group type: EXPERIMENTAL
Intervention: RDT subsidised arms
Number of subjects: 842
Study 33148541 — intervention group
Group type: EXPERIMENTAL
Intervention: RDT positives taking ACT
Number of subjects: 842
Study 33148541 — intervention group
Group type: EXPERIMENTAL
Intervention: RDT negatives not taking ACT
Number of subjects: 842
Study 33148541 — intervention group
Group type: COMPARATOR
Intervention: Conditional ACT subsidy
Number of subjects: 842
Study 35984496 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent bilateral anodal tDCS of primary motor cortex and cerebellum (2 mA, 20 min)
Number of subjects: 21
Study 35984496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cerebellar stimulation (2 mA, 20 min)
Number of subjects: 21
Study 35984496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral anodal tDCS of primary motor cortex (2 mA, 20 min)
Number of subjects: 21
Study 35984496 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study 33879680 — intervention group
Group type: EXPERIMENTAL
Intervention: Biqi capsule combined with diclofenac sodium sustained release tablets
Number of subjects: 0
Study 33879680 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium sustained-release tablets alone
Number of subjects: 0
Study 33879045 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cerebral perfusion (ACP)
Number of subjects: 76
Study 33879045 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde inferior vena caval perfusion (RIVP) + ACP
Number of subjects: 76
Study 33879045 — intervention group
Group type: EXPERIMENTAL
Intervention: RIVP + ACP
Number of subjects: 76
Study 32012411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy 200 mg every 3 weeks for 2 years or until progression, death, unacceptable toxicity or consent withdrawal
Number of subjects: 21
Study 32012411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 21
Study 34971040 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach Pepper (socially assistive humanoid robot system)
Number of subjects: 32
Study 34971040 — intervention group
Group type: COMPARATOR
Intervention: Tablet-based training
Number of subjects: 32
Study 33259536 — intervention group
Group type: EXPERIMENTAL
Intervention: GoPro led feedback
Number of subjects: 71
Study 33259536 — intervention group
Group type: COMPARATOR
Intervention: Non-GoPro led feedback
Number of subjects: 71
Study 34266750 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation self-help intervention
Number of subjects: 332
Study 34266750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 332
Study 34266750 — intervention group
Group type: EXPERIMENTAL
Intervention: Health related quality of life
Number of subjects: 332
Study 32266572 — intervention group
Group type: EXPERIMENTAL
Intervention: Near Infrared (NIR) fluorescence
Number of subjects: 121
Study 32266572 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiocolloids (RC)
Number of subjects: 121
Study 32266572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent blue dye
Number of subjects: 121
Study 32266572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three techniques (NIR, blue dye, RC)
Number of subjects: 121
Study 32266572 — intervention group
Group type: COMPARATOR
Intervention: Overall results
Number of subjects: 121
Study 33565237 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated multivariable-adjusted Cox models, CART, and logistic regression analysis
Number of subjects: 8399
Study 33565237 — intervention group
Group type: EXPERIMENTAL
Intervention: CART analysis
Number of subjects: 8399
Study 33565237 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes over time in heart rate, NYHA class, blood urea nitrogen and albumin levels
Number of subjects: 8399
Study 34401422 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-TXA (15 mg/kg)
Number of subjects: 108
Study 34401422 — intervention group
Group type: EXPERIMENTAL
Intervention: IA-TXA (2 g)
Number of subjects: 108
Study 34401422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA injection)
Number of subjects: 108
Study 32571570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methods
Number of subjects: 0
Study 34332584 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily for 24 weeks
Number of subjects: 105
Study 35871907 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTREN-F program (family-system-based intervention)
Number of subjects: 0
Study 35871907 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTREN program (without specific family-system-based workshop)
Number of subjects: 0
Study 35871907 — intervention group
Group type: COMPARATOR
Intervention: Control group (behavioral monitoring)
Number of subjects: 0
Study 35871907 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTREN-F program
Number of subjects: 0
Study 35871907 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTREN program
Number of subjects: 0
Study 35871907 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34037768 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual tailored message
Number of subjects: 304
Study 34037768 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation targeted message
Number of subjects: 304
Study 34037768 — intervention group
Group type: COMPARATOR
Intervention: Generic message
Number of subjects: 304
Study 34037768 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages with financial information
Number of subjects: 304
Study 34037768 — intervention group
Group type: COMPARATOR
Intervention: Messages without financial information
Number of subjects: 304
Study 35202432 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplements orally twice a day for 3 months
Number of subjects: 160
Study 35202432 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements orally twice a day for 3 months
Number of subjects: 160
Study 32505405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cornual nerve block plus meloxicam (LCM)
Number of subjects: 140
Study 32505405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cornual nerve block (LC) and Lidocaine cornual nerve block plus meloxicam (LCM)
Number of subjects: 140
Study 32505405 — intervention group
Group type: COMPARATOR
Intervention: Sham control (SH)
Number of subjects: 140
Study 35644993 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiovascular rehabilitation program (CR) with 3 weekly exercise sessions for 6 months
Number of subjects: 0
Study 34311563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 1000 eggs and juveniles of M. javanica
Number of subjects: 1230
Study 34311563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 2000 eggs and juveniles of M. javanica
Number of subjects: 1230
Study 34311563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 5000 eggs and juveniles of M. javanica
Number of subjects: 1230
Study 34311563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 10000 eggs and juveniles of M. javanica
Number of subjects: 1230
Study 34311563 — intervention group
Group type: COMPARATOR
Intervention: Inoculation with 0 eggs and juveniles of M. javanica
Number of subjects: 1230
Study 34311563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with an unidentified species of Meloidogyne
Number of subjects: 1230
Study 32199790 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive uptake after miscarriage
Number of subjects: 244
Study 32199790 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned pregnancy
Number of subjects: 244
Study 32199790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of intention to continue the pregnancy
Number of subjects: 244
Study 32199790 — intervention group
Group type: EXPERIMENTAL
Intervention: Declined contraception
Number of subjects: 244
Study 32199790 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned pregnancy description
Number of subjects: 244
Study 35895508 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab (CAS + IMD) 2.4 g
Number of subjects: 1336
Study 35895508 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab (CAS + IMD) 8.0 g
Number of subjects: 1336
Study 35895508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1336
Study 33798921 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + EFT + CM
Number of subjects: 54
Study 33798921 — intervention group
Group type: COMPARATOR
Intervention: CBT + EFT
Number of subjects: 54
Study 34344834 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive with abnormal cytology
Number of subjects: 1133
Study 34344834 — intervention group
Group type: COMPARATOR
Intervention: Control group (HPV negative/HPV cleared/normal cytology and not tested for HPV)
Number of subjects: 1133
Study 34344834 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive with normal cytology
Number of subjects: 1133